AstraZeneca partners on diabetes, obesity drugs; Gilead reports idelalisib data on NHL; MannKind completes PhIII Afrezza study;

@FierceBiotech: ICYMI: Merck's new R&D chief Perlmutter begins major shakeup. Report | Follow @FierceBiotech

 @JohnCFierce: J&J snags another promising prostate cancer drug in $1B Aragon buyout. News | Follow @JohnCFierce

@RyanMFierce: 2013 Fierce 15 survey: Tell us who you think will be the next Aragon or privately held biotech to get acquired. Submit your nominations now | Follow @RyanMFierce

 @EmilyMFierce: Inovio says H7N9 bird flu vaccine effective in mice. Article | Follow @EmilyMFierce

> AstraZeneca ($AZN) has struck a deal to partner with NGM Biopharmaceuticals on a discovery deal related to NGM's enteroendocrine cell (EEC) program for diabetes and obesity drugs. Release

> Gilead Sciences ($GILD) says that interim results from a single-arm, open-label Phase II study of idelalisib in patients with indolent non-Hodgkin's lymphoma demonstrated an overall response rate of 53.6 percent, with a median duration of response at this interim analysis of 11.9 months. Release

> MannKind's long-awaited Phase III follow-up study for Afrezza has been completed, paving the way to an announcement on the data later this summer. Release

Medical Device News

@FierceMedDev: Amaranth's dissolving cardiac stent drives $25M fundraising round. Story | Follow @FierceMedDev

@DamianFierce: ADC superstar Ambrx is reaching out to WuXi to develop a cancer drug of its own. From FierceCRO | Follow @DamianFierce

@MarkHFierce: Curious to hear from readers--what device and diagnostics companies do you see as major M&A targets through the rest of 2013? LinkedIn discussion | Follow @MarkHFierce

@MichaelGFierce: Drug-carrying 'nanovolcanoes' make precise delivery structures. From FierceDrugDelivery | Follow @MichaelGFierce

> German court upholds Medtronic's CoreValve heart pump patent. Article

> More diagnostics companies pounce in wake of SCOTUS gene decision. Item

> J&J/Mentor wins U.S. sign-off for silicone breast implant, with conditions. More

Pharma News

@FiercePharma: Supremes rule in pay-for-delay case: 5-3 vote slaps down AbbVie/Actavis plea for protection from lawsuits over patent settlements. | Follow @FiercePharma

@EricPFierce: India's Wockhardt in serious hurt between FDA import alert and India's decision to pull pain drug. Story | Follow @EricPFierce

> Supreme Court slaps pharma aside in pay-for-delay ruling. News

> With $135M rights deal, Questcor locks up rival to its pricey Acthar drug. Story

> Novo's quick-selling Victoza threatened by Lilly diabetes hopeful. More

CRO News

> Synexus wins Pfizer's favor for South African trials. More

> Ash Stevens signs on for Ariad's blockbuster contender. Item

> Ambrx taps WuXi for HER2-targeting cancer drug. Report

> Almac adding 229 jobs in Irish CMO expansion. Article

> Catalent puts $35M into CMO plant. Story

> MPI teams up with imaging outfits to woo drug developers. News

Biotech IT News

> Berkeley professor: Genomic data leaks seem inevitable. More

> Cancer Research UK mulls multiple video game options. Report

> 23andMe seeks consumer boost in long-range data strategy. Story

> FDA joins chorus of concern about cybersecurity threats. More

> Firm tries startup's tech tricks for clinical trial recruitment. Article

And Finally… A new study shows that men who suffer from restless leg syndrome also face a significantly higher risk of death. Story

Suggested Articles

IBM and Pfizer developed an artificial intelligence model that could eventually predict if a person will develop Alzheimer’s using a language test.

After teaming up with other Big Pharmas to bolster antibiotics research, Pfizer is adding a new antibiotic prospect to its pipeline.

The oral direct-acting antiviral is set to enter a phase 3 trial in non-hospitalized patients early next year.